(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that the first participants were dosed in the OPUS (OPA-based Pivotal U.S. Study) Phase 3 pivotal, noninferiority trial ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

"Epcoritamab and R 2 is a novel chemotherapy-free fixed-duration therapy that is suitable for outpatient administration and, we believe, sets a new benchmark as a standard of care for second-line [or ...

Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...

It’s not uncommon to hear Americans of all races and ethnicities say they don’t trust the organ donation system. But the ...

Research with 50 cancer patients reveals fuzzy socks and care packages often miss the mark. Discover what people with cancer ...